AR and prostate cancer: Interestingly, Raina and his colleagues demonstrated that ARV‐771, a small molecule–based PROTAC using pan‐BET inhibitors suppressed both AR protein level and AR signalling, dramatically improved the efficacy in cellular models of castrate resistance prostate cancer (CRPC).68